CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases.

India's Department of Pharmaceuticals (DoP) has reopened the Production Linked Incentive (PLI) scheme for bulk drugs, ...

CorMedix announces $128.6 million of net revenue for the fourth quarter of 2025, largely driven by continued utilization of DefenCath by its outpatient dialysis customers. DefenCath sales contributed ...

Q4 2025 Net Revenue of $128.6 million - Pro Forma Full Year 2025 Net Revenue of $401.3 million - Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million - Conference Call Scheduled for ...

Antimicrobial resistance is the ability of microorganisms such as bacteria, fungi or protozoans to grow despite exposure to antimicrobial substances designed to inhibit their growth. Microbes can ...

Antibiotics are substances that inhibit the growth of bacteria. They work by killing bacteria or preventing their reproduction, and may be synthesized chemically or by naturally-occurring or ...

This leaflet answers some common questions about Meropenem GH. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have ...

Azithromycin is often the first-line treatment for bacterial pneumonia. Amoxicillin is used for mild to moderate pneumonia for nonhospitalized people. Hospitalized adults may need different ...